title: Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
abstract: Limited data is available about the factors affecting early immune recovery or its clinical significance after autologous stem cell transplantation (auto-SCT). We prospectively analyzed factors affecting early immune recovery and outcome among 72 non-Hodgkin lymphoma (NHL) patients. Absolute lymphocyte count 15 d after auto-SCT (ALC-15) ≥ 0.5 × 10(9)/L was associated with the use of plerixafor (p = 0.004), the number of CD34(+) cells (p = 0.015), and CD34(+) CD38(-) cells (p = 0.005) in the grafts. ALC-15 ≥ 0.5 × 10(9)/L was associated with improved overall survival (p = 0.021). In patients with aggressive histology, ALC-15 ≥ 0.5 × 10(9)/L was beneficial in regard to both progression-free survival (p = 0.015) and overall survival (p = 0.002). Early immune recovery seems to be important in transplanted patients with NHL and, therefore, an easy and affordable method for disease-related risk analysis. Patients with aggressive histology and slow immune recovery may need additional post-transplant treatment.
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Jaakko
authors.initials: J
authors.lastname: Valtola
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Ville
authors.initials: V
authors.lastname: Varmavuo
authors.affiliation: b Department of Clinical Microbiology , University of Eastern Finland , Kuopio , Finland ;
authors.forename: Antti
authors.initials: A
authors.lastname: Ropponen
authors.affiliation: c Science Service Center, Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Tuomas
authors.initials: T
authors.lastname: Selander
authors.affiliation: d Department of Oncology , Oulu University Hospital , Oulu , Finland ;
authors.forename: Outi
authors.initials: O
authors.lastname: Kuittinen
authors.affiliation: d Department of Oncology , Oulu University Hospital , Oulu , Finland ;
authors.forename: Hanne
authors.initials: H
authors.lastname: Kuitunen
authors.affiliation: e Department of Oncology , Tampere University Hospital , Tampere , Finland ;
authors.forename: Leena
authors.initials: L
authors.lastname: Keskinen
authors.affiliation: f Department of Oncology , Central Hospital of Central Finland , Jyväskylä , Finland ;
authors.forename: Kaija
authors.initials: K
authors.lastname: Vasala
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Tapio
authors.initials: T
authors.lastname: Nousiainen
authors.affiliation: g Laboratory Center of Eastern Finland , Kuopio , Finland.
authors.forename: Pentti
authors.initials: P
authors.lastname: Mäntymaa
authors.affiliation: b Department of Clinical Microbiology , University of Eastern Finland , Kuopio , Finland ;|g Laboratory Center of Eastern Finland , Kuopio , Finland.
authors.forename: Jukka
authors.initials: J
authors.lastname: Pelkonen
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Esa
authors.initials: E
authors.lastname: Jantunen
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006085:Graft Survival / Q000276:immunology; D006410:Hematopoiesis; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D007109:Immunity; D018655:Lymphocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019233:Retreatment; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
keywords: ALC-15; Autologous transplantation; graft analysis; immune recovery; non-Hodgkin lymphoma; outcome